OBJECTIVE: Azathioprine (AZA) and mycophenolate mofetil (MMF) are immunosuppressants frequently used in the treatment of moderate-to-severe systemic lupus erythematosus (SLE). We studied longitudinal patterns and predictors of adherence to AZA and MMF in a nationwide US SLE cohort. METHODS: In the Medicaid Analytic eXtract (2000-2010) database, we identified patients with SLE who initiated AZA or MMF (no use in the prior 6 months) with ≥12 months of continuous follow-up. We dichotomized adherence at 80%, with ≥24 of 30 days per month considered adherent. We used group-based trajectory models to estimate monthly adherence patterns and multivariable multinomial logistic regression to determine the association between demographic, SLE and utilization-related predictors, and the odds ratios (OR) of belonging to a nonadherent versus the adherent trajectory, separately for AZA and MMF. RESULTS: We identified 2,309 AZA initiators and 2,070 MMF initiators with SLE. Four-group trajectory models classified 17% of AZA and 21% of MMF initiators as adherent. AZA and MMF nonadherers followed similar trajectory patterns. African American race (OR 1.67 [95% confidence interval (95% CI) 1.20-2.31]) and Hispanic ethnicity (OR 1.58 [95% CI 1.06-2.35]) increased odds of AZA nonadherence; there were no significant associations between race/ethnicity and MMF nonadherence. Male sex and polypharmacy were associated with lower odds of nonadherence to both medications; lupus nephritis was associated with lower odds of nonadherence to MMF (OR 0.74 [95% CI 0.55-0.99]). CONCLUSION: Adherence to AZA or MMF over the first year of use was rare. Race, sex, and lupus nephritis were modestly associated with adherence, but the magnitude, direction, and significance of predictors differed by medication, suggesting the complexity of predicting adherence behavior.
OBJECTIVE:Azathioprine (AZA) and mycophenolate mofetil (MMF) are immunosuppressants frequently used in the treatment of moderate-to-severe systemic lupus erythematosus (SLE). We studied longitudinal patterns and predictors of adherence to AZA and MMF in a nationwide US SLE cohort. METHODS: In the Medicaid Analytic eXtract (2000-2010) database, we identified patients with SLE who initiated AZA or MMF (no use in the prior 6 months) with ≥12 months of continuous follow-up. We dichotomized adherence at 80%, with ≥24 of 30 days per month considered adherent. We used group-based trajectory models to estimate monthly adherence patterns and multivariable multinomial logistic regression to determine the association between demographic, SLE and utilization-related predictors, and the odds ratios (OR) of belonging to a nonadherent versus the adherent trajectory, separately for AZA and MMF. RESULTS: We identified 2,309 AZA initiators and 2,070 MMF initiators with SLE. Four-group trajectory models classified 17% of AZA and 21% of MMF initiators as adherent. AZA and MMF nonadherers followed similar trajectory patterns. African American race (OR 1.67 [95% confidence interval (95% CI) 1.20-2.31]) and Hispanic ethnicity (OR 1.58 [95% CI 1.06-2.35]) increased odds of AZA nonadherence; there were no significant associations between race/ethnicity and MMF nonadherence. Male sex and polypharmacy were associated with lower odds of nonadherence to both medications; lupus nephritis was associated with lower odds of nonadherence to MMF (OR 0.74 [95% CI 0.55-0.99]). CONCLUSION: Adherence to AZA or MMF over the first year of use was rare. Race, sex, and lupus nephritis were modestly associated with adherence, but the magnitude, direction, and significance of predictors differed by medication, suggesting the complexity of predicting adherence behavior.
Authors: Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman Journal: Arthritis Care Res (Hoboken) Date: 2012-06 Impact factor: 4.794
Authors: Jessica M Franklin; William H Shrank; Juliana Pakes; Gabriel Sanfélix-Gimeno; Olga S Matlin; Troyen A Brennan; Niteesh K Choudhry Journal: Med Care Date: 2013-09 Impact factor: 2.983
Authors: Candace H Feldman; Jamie Collins; Zhi Zhang; S V Subramanian; Daniel H Solomon; Ichiro Kawachi; Karen H Costenbader Journal: Semin Arthritis Rheum Date: 2018-01-08 Impact factor: 5.532
Authors: Araceli Garcia-Gonzalez; Marsha Richardson; Maria Garcia Popa-Lisseanu; Vanessa Cox; Michael A Kallen; Namieta Janssen; Bernard Ng; Donald M Marcus; John D Reveille; Maria E Suarez-Almazor Journal: Clin Rheumatol Date: 2008-01-08 Impact factor: 2.980
Authors: Kai Sun; Amanda M Eudy; Jennifer L Rogers; Lisa G Criscione-Schreiber; Rebecca E Sadun; Jayanth Doss; Mithu Maheswaranathan; Ann Cameron Barr; Lena Eder; Amy L Corneli; Hayden B Bosworth; Megan E B Clowse Journal: Arthritis Care Res (Hoboken) Date: 2021-11-05 Impact factor: 5.178
Authors: Christopher F Bell; Julie Priest; Marni Stott-Miller; Hong Kan; Justyna Amelio; Xue Song; Brendan Limone; Virginia Noxon; Karen H Costenbader Journal: Lupus Sci Med Date: 2020-03-26
Authors: May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader Journal: Rheumatology (Oxford) Date: 2021-08-02 Impact factor: 7.580
Authors: Katherine P Pryor; Medha Barbhaiya; Karen H Costenbader; Candace H Feldman Journal: Rheum Dis Clin North Am Date: 2020-10-29 Impact factor: 2.670
Authors: Yemil Atisha-Fregoso; Susan Malkiel; Kristina M Harris; Margie Byron; Linna Ding; Sai Kanaparthi; William T Barry; Wendy Gao; Kristin Ryker; Patti Tosta; Anca D Askanase; Susan A Boackle; W Winn Chatham; Diane L Kamen; David R Karp; Kyriakos A Kirou; S Sam Lim; Bradley Marder; Maureen McMahon; Samir V Parikh; William F Pendergraft; Amber S Podoll; Amit Saxena; David Wofsy; Betty Diamond; Dawn E Smilek; Cynthia Aranow; Maria Dall'Era Journal: Arthritis Rheumatol Date: 2020-12-01 Impact factor: 15.483